GSK Investigational Site

Normal, Illinois 61761

1 studies enrolling now · 24 studies all time

What they study most

Activity/Exercise Induced Bronchospasm, Asthma, Atherosclerosis, Bronchospasm, Cough, Fibrillation, Atrial, Pulmonary Disease, Chronic Obstructive, Refractory Chronic Cough, Restless Legs Syndrome, Restless Legs Syndrome (RLS), Rhinitis, Allergic, Seasonal

Studies at this site

• A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma — Recruiting now
• A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough — Completed
• Pragmatic Open - Label Randomized Clinical Trial of FF/UMEC/VI vs Non-ellipta Usual Care ICS-LABA for Adult Participants With Uncontrolled Asthma — Running, not enrolling
• An Open-Label Extension Study of GSK3511294 (Depemokimab) in Participants Who Were Previously Enrolled in 206713 (NCT04719832) or 213744 (NCT04718103) — Completed
• Placebo-controlled Efficacy and Safety Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype — Completed
• A Phase III Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination (FDC) of Fluticasone Furoate+Umeclidinium Bromide+Vilanterol (FF/UMEC/VI) With the FDC of FF/VI in Subjects With Inadequately Controlled Asthma — Completed
• 6-month Safety and Benefit Study of ADVAIR in Children 4-11 Years Old — Completed
• SAS115359: A 6-month Study to Assess the Safety and Benefit of Inhaled Fluticasone Propionate/Salmeterol Combination Compared With Inhaled Fluticasone Propionate in the Treatment of Adolescents and Adults (12 Years of Age and Older) With Asthma. — Completed
• A Study to Assess the Efficacy of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25 mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50 mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD) — Completed
• Study HZA106827: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642444) in Adult and Adolescent Asthmatics — Completed
• An Efficacy and Safety Study of Fluticasone Furoate/Vilanterol (FF/VI) 200/25 Microgram (mcg) , FF/VI 100/25 mcg, and FF 100 mcg in Adults and Adolescents With Persistent Asthma. — Completed
• FLOVENT Hydrofluoroalkane (HFA) In 6-12 Month Old Subjects — Completed
• A Dose-ranging Study of Fluticasone Furoate (FF) — Completed
• Pharmacokinetics and PharmacoDynamics of GW685698 in Paedeatric Asthmatic Patients — Completed
• Evaluation of Efficacy and Safety of Lovaza (Omega-3-Acid Ethyl Esters) in Recurrent, Symptomatic Atrial Fibrillation — Completed
• Pharmacokinetics and Pharacodynamics of GW642444 in Paedetric Subjects — Completed
• Study HZA106829: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642444) in Adult and Adolescent Asthmatics — Completed
• Dose-ranging Study of Vilanterol (VI) Inhalation Powder in Children — Completed
• Fluticasone Furoate Nasal Spray Versus Oral Fexofenadine — Completed
• A Study To Determine The Effect Of SB-480848 On Asthma — Completed
• 12-week Polysomnography Study of Ropinirole Controlled Release for Restless Legs Syndrome — Completed
• Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease) — Completed
• A Study Measuring Asthma Control In Pediatric And Adolescent Subjects Whose Asthma Is Worsened By Activity Or Exercise — Completed
• GSK BHR Study (Sont) — Completed